Une révolution thérapeutique en rhumatologie : oui, mais….

Biological therapies; Monoclonal antibodies; Rheumatology; Drug clinical research; Tumor Necrosis Factor-alpha; Humans; Arthritis, Psoriatic; Arthritis, Rheumatoid; Polymyalgia Rheumatica; Rheumatology/trends; Medicine (all)

Abstract :

[en] The development of new drugs is a significant activity in a university hospital that favors access to therapeutic novelties to patients. Rheumatology, whose drug armamentarium was poor in the 1980s, has benefited from the huge progresses of immunology in the 1980-1990s, allowing a therapeutic revolution in whom the academic hospital of Liège (CHU Liège) has been strongly implicated. First protocols with anti-TNF-? monoclonal antibodies have been applied in 1997. Sixty-one protocols have been initiated in rheumatoid arthritis, 12 in ankylosing spondylitis, 10 in psoriatic arthritis, 9 in systemic erythematosus lupus, 3 in giant cell arteritis, 1 in polymyalgia rheumatica, 5 in osteoarthritis and 4 in osteoporosis. Potential and pitfalls will be discussed disease by disease and also by drug categories. The balance remains globally positive, but remission is far from be reached.
[fr] La recherche clinique médicamenteuse est une activité importante dans un hôpital universitaire. Elle valide des nouveautés thérapeutiques et fait bénéficier les patients de traitements novateurs bien avant leur mise sur le marché. La rhumatologie est une discipline dont l’arsenal thérapeutique était pauvre dans les années 1980, et les immenses progrès de l’immunologie, réalisés entre 1980 et 1995, lui ont permis de vivre une véritable révolution thérapeutique à laquelle notre service a amplement participé. C’est en 1997 que les premiers traitements par anticorps monoclonaux anti-TNF-? (les traitements dits biologiques) ont été utilisés au CHU de Liège. Soixante et une études seront initiées dans la polyarthrite rhumatoïde, 12 dans la spondylarthrite ankylosante, 10 dans la polyarthrite psoriasique, 9 dans le lupus érythémateux disséminé, 3 dans l’artérite temporale de Horton, une dans la pseudopolyarthrite rhizomélique, une dans la sclérodermie, 5 dans l’arthrose, 4 dans l’ostéoporose. Les espoirs et les déceptions observées dans les différentes indications, et avec les différentes molécules, sont analysées. Le bilan est globalement positif, mais les résultats encore insuffisants que pour arriver au concept de rémission.

Disciplines :

Rheumatology

Author, co-author :

MALAISE, Michel ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

CHAPELIER, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive

DEWAEL, Thibaut ; Centre Hospitalier Universitaire de Liège - CHU > > Frais communs médecine - Pool assistants

LEONORI, Lorenzo ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

LEROY, Mathieu ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

Mailleux, E; ) Service de Rhumatologie, CHU Liège, Belgique

André, Béatrice ; Centre Hospitalier Universitaire de Liège - CHU

Halleux, Sandrine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

KAISER, Marie-Joëlle ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

MALAISE, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie

More authors (4 more)

Language :

French

Title :

Une révolution thérapeutique en rhumatologie : oui, mais….

Alternative titles :

[en] Remarkable medical advances in rheumatology : may be….

Publication date :

May 2020

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Revue Medicale de Liege, Belgium

Volume :

Issue :

5-6

Pages :

369-375

Peer reviewed :

Editorial Reviewed verified by ORBi

Available on ORBi :

since 22 April 2022

Statistics

Number of views

185 (15 by ULiège)

Number of downloads

8 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260:2345-54.
Beutler B, Mahoney J, Le Trang N, et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxininduced RAW 264.7 cells. J Exp Med 1985;161:984-95.
Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4.
Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
Dayer JM, Graham R, Russell G, et al. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science 1977;195:181-3.
Dayer JM, Robinson DR, Krane SM. Prostaglandin production by rheumatoid synovial cells : stimulation by a factor from human mononuclear cells. J Exp Med 1977;145:1399-404.
Dayer JM, Stephenson ML, Schmidt E, et al. Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett 1981;124:253.
Mizel SB, Dayer JM, Krane SM, et al. Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-Activating factor (interleukin 1). Proc Natl Acad Sci USA 1981;78:2474-7.
Dayer JM. From supernatants to cytokines : A personal view on the early history of IL-1, IL-1Ra, TNF and its inhibitor in rheumatology. Arthritis Res Ther 2018;20:101.
Balavoine JF, de Rochemonteix B, Williamson K, et al. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest 1986;78:1120-4.
Seckinger P, Williamson K, Balavoine JF, et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol 1987;139:1541-5.
Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987;139:1546-9.
Prieur AM, Kaufmann MT, Griscelli C, et al. Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987;2:1240-2.
Feldmann M, Brennan FM, Williams RO, et al. Evaluation of the role of cytokines in autoimmune disease: The importance of TNF alpha in rheumatoid arthritis. Prog Growth Factor Res 1992;4:247-55.
Dinarello CA. Interleukin-1. Rev Infect Dis 1984;6:51-95.
Seckinger P, Zhang JH, Hauptmann B, et al. Characterization of a tumor necrosis factor alpha (TNF-Alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990;87:5188-92.
Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
Elliott MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-Tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
Dougados M, Gueguen A, Nakache JP, et al. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 1999;26:971-4.
Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018;77:1295-302.
Siebert S, Millar NL, McInnes Iain B. Why did IL-23p19 inhibition fail in AS : A tale of tissues, trials or translation? Ann Rheum Dis 2019;78:1015-18.
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
Targan SR, Feagan B, Vermeire S, et al. A randomized, doubleblind, placebo-controlled phase 2 study of brodalumab in patients with moderate-To-severe Crohn's disease. Am J Gastroenterol 2016;111:1599-607.
Malaise O, von Frenckell C, André B, et al. The management of systemic lupus erythematosus with biological therapies. Rev Med Suisse 2013;9:1507-11.
Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90.
Clowse ME, Wallace DJ, Furie RA, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus : results from two phase III randomized, doubleblind, placebo-controlled trials. Arthritis Rheumatol 2017;69:362-75.
Haute Autorité de la Santé, France. https://www.has-sante.fr/
Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomized, controlled, phase 3 trial. The Lancet Rheumatology 2019:1:p.e208-e219.
Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211-21.
Cid MC, Gandhi R, Corbera-Bellalta M, et al. Thu0008 GM-CSF pathway signature identified in temporal artery biopsies of patients with giant cell arteritis. Ann Rheum Dis 2019; 78: 271-2.
Umeda M, Ikenaga J, Koga T, et al. Giant cell arteritis which developed after the administration of Granulocyte-colony Stimulating Factor for cyclic neutropenia. Intern Med 2016;55:2291-4.
Stone JH, Tuckwell K, Dimonaco S, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab. Arthritis Rheumatol 2019;71:1329-38.
Kloppenburg M, Peterfy C, Haugen IK, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an antiinterleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis 2019;78:413-20.
Fleischmann RM, Bliddal H, Blanco FJ, et al. A phase II trial of lutikizumab, an anti-Interleukin-1α/β dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol 2019;71:1056-69.
Önnerfjord P, Khabut A, Reinholt FP, et al. Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. J Biol Chem 2012;287:18913-24.
Lourido L, Calamia V, Mateos J, et al. Quantitative proteomic profiling of human articular cartilage degradation in osteoarthritis. J Proteome Res 2014;13:6096-106.
de Seny D, Sharif M, Fillet M, et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis 2011;70:1144-52.
Cobraiville G, Fillet M, Sharif M, et al. Validation of a new method by nano-liquid chromatography on chip tandem mass spectrometry for combined quantitation of C3f and the V65 vitronectin fragment as biomarkers of diagnosis and severity of osteoarthritis. Talanta 2017;169:170-80.
Deroyer C, Charlier E, Neuville S, et al. CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes. Cell Death Dis 2019;10:103.
Malaise O, Tachikart Y, Constantinides M, et al. Mesenchymal stem cell senescence alleviates their intrinsic and seno-suppressive paracrine properties contributing to osteoarthritis development. Aging (Albany NY) 2019;11:9128-46.
Malaise MG. The non-recommendations in the treatment of osteoarthritis and rheumatoid arthritis, or why is evidence-based medicine so difficult (still) to apply to rheumatology?. Rev Med Liege 2000;55:466-75.
Burmester GR, Pope JE Novel treatment strategies in rheumatoid arthritis. Lancet 2017;389:2338-48.